Depression rating scales in Parkinson's disease: Critique and recommendations
Identifieur interne : 001342 ( Main/Corpus ); précédent : 001341; suivant : 001343Depression rating scales in Parkinson's disease: Critique and recommendations
Auteurs : Anette Schrag ; Paolo Barone ; Richard G. Brown ; Albert F. G. Leentjens ; William M. Mcdonald ; Sergio Starkstein ; Daniel Weintraub ; Werner Poewe ; Olivier Rascol ; Cristina Sampaio ; Glenn T. Stebbins ; Christopher G. GoetzSource :
- Movement Disorders [ 0885-3185 ] ; 2007-06-15.
English descriptors
Abstract
Depression is a common comorbid condition in Parkinson's disease (PD) and a major contributor to poor quality of life and disability. However, depression can be difficult to assess in patients with PD due to overlapping symptoms and difficulties in the assessment of depression in cognitively impaired patients. As several rating scales have been used to assess depression in PD (dPD), the Movement Disorder Society commissioned a task force to assess their clinimetric properties and make clinical recommendations regarding their use. A systematic literature review was conducted to explore the use of depression scales in PD and determine which scales should be selected for this review. The scales reviewed were the Beck Depression Inventory (BDI), Hamilton Depression Scale (Ham‐D), Hospital Anxiety and Depression Scale (HADS), Zung Self‐Rating Depression Scale (SDS), Geriatric Depression Scale (GDS), Montgomery‐Asberg Depression Rating Scale (MADRS), Unified Parkinson's Disease Rating Scale (UPDRS) Part I, Cornell Scale for the Assessment of Depression in Dementia (CSDD), and the Center for Epidemiologic Studies Depression Scale (CES‐D). Seven clinical researchers with clinical and research experience in the assessment of dPD were assigned to review the scales using a structured format. The most appropriate scale is dependent on the clinical or research goal. However, observer‐rated scales are preferred if the study or clinical situation permits. For screening purposes, the HAM‐D, BDI, HADS, MADRS, and GDS are valid in dPD. The CES‐D and CSDD are alternative instruments that need validation in dPD. For measurement of severity of depressive symptoms, the Ham‐D, MADRS, BDI, and SDS scales are recommended. Further studies are needed to validate the CSDD, which could be particularly useful for the assessment of severity of dPD in patients with comorbid dementia. To account for overlapping motor and nonmotor symptoms of depression, adjusted instrument cutoff scores may be needed for dPD, and scales to assess severity of motor symptoms (e.g., UPDRS) should also be included to help adjust for confounding factors. The HADS and the GDS include limited motor symptom assessment and may, therefore, be most useful in rating depression severity across a range of PD severity; however, these scales appear insensitive in severe depression. The complex and time‐consuming task of developing a new scale to measure depression specifically for patients with PD is currently not warranted. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21333
Links to Exploration step
ISTEX:E10BA9A996EAA2019D3CAC78E33B7FE57DA9CEA7Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Depression rating scales in Parkinson's disease: Critique and recommendations</title><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, London NW3 2PF, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name><affiliation><mods:affiliation>Department of Neurological Sciences, University of Napoli Federico II, Naples, Italy</mods:affiliation></affiliation></author><author><name sortKey="Brown, Richard G" sort="Brown, Richard G" uniqKey="Brown R" first="Richard G." last="Brown">Richard G. Brown</name><affiliation><mods:affiliation>King's College London, MRC Neurodegeneration Research Centre, Institute of Psychiatry, Department of Psychology, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name><affiliation><mods:affiliation>Department of Psychiatry, Maastricht University Hospital, Maastricht, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Mcdonald, William M" sort="Mcdonald, William M" uniqKey="Mcdonald W" first="William M." last="Mcdonald">William M. Mcdonald</name><affiliation><mods:affiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA</mods:affiliation></affiliation></author><author><name sortKey="Starkstein, Sergio" sort="Starkstein, Sergio" uniqKey="Starkstein S" first="Sergio" last="Starkstein">Sergio Starkstein</name><affiliation><mods:affiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Australia</mods:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E10BA9A996EAA2019D3CAC78E33B7FE57DA9CEA7</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21333</idno><idno type="url">https://api.istex.fr/document/E10BA9A996EAA2019D3CAC78E33B7FE57DA9CEA7/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001342</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Depression rating scales in Parkinson's disease: Critique and recommendations</title><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, London NW3 2PF, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name><affiliation><mods:affiliation>Department of Neurological Sciences, University of Napoli Federico II, Naples, Italy</mods:affiliation></affiliation></author><author><name sortKey="Brown, Richard G" sort="Brown, Richard G" uniqKey="Brown R" first="Richard G." last="Brown">Richard G. Brown</name><affiliation><mods:affiliation>King's College London, MRC Neurodegeneration Research Centre, Institute of Psychiatry, Department of Psychology, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name><affiliation><mods:affiliation>Department of Psychiatry, Maastricht University Hospital, Maastricht, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Mcdonald, William M" sort="Mcdonald, William M" uniqKey="Mcdonald W" first="William M." last="Mcdonald">William M. Mcdonald</name><affiliation><mods:affiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA</mods:affiliation></affiliation></author><author><name sortKey="Starkstein, Sergio" sort="Starkstein, Sergio" uniqKey="Starkstein S" first="Sergio" last="Starkstein">Sergio Starkstein</name><affiliation><mods:affiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Australia</mods:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-06-15">2007-06-15</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1077">1077</biblScope><biblScope unit="page" to="1092">1092</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E10BA9A996EAA2019D3CAC78E33B7FE57DA9CEA7</idno><idno type="DOI">10.1002/mds.21333</idno><idno type="ArticleID">MDS21333</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>depression</term><term>psychiatric status rating scales</term><term>psychometrics</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Depression is a common comorbid condition in Parkinson's disease (PD) and a major contributor to poor quality of life and disability. However, depression can be difficult to assess in patients with PD due to overlapping symptoms and difficulties in the assessment of depression in cognitively impaired patients. As several rating scales have been used to assess depression in PD (dPD), the Movement Disorder Society commissioned a task force to assess their clinimetric properties and make clinical recommendations regarding their use. A systematic literature review was conducted to explore the use of depression scales in PD and determine which scales should be selected for this review. The scales reviewed were the Beck Depression Inventory (BDI), Hamilton Depression Scale (Ham‐D), Hospital Anxiety and Depression Scale (HADS), Zung Self‐Rating Depression Scale (SDS), Geriatric Depression Scale (GDS), Montgomery‐Asberg Depression Rating Scale (MADRS), Unified Parkinson's Disease Rating Scale (UPDRS) Part I, Cornell Scale for the Assessment of Depression in Dementia (CSDD), and the Center for Epidemiologic Studies Depression Scale (CES‐D). Seven clinical researchers with clinical and research experience in the assessment of dPD were assigned to review the scales using a structured format. The most appropriate scale is dependent on the clinical or research goal. However, observer‐rated scales are preferred if the study or clinical situation permits. For screening purposes, the HAM‐D, BDI, HADS, MADRS, and GDS are valid in dPD. The CES‐D and CSDD are alternative instruments that need validation in dPD. For measurement of severity of depressive symptoms, the Ham‐D, MADRS, BDI, and SDS scales are recommended. Further studies are needed to validate the CSDD, which could be particularly useful for the assessment of severity of dPD in patients with comorbid dementia. To account for overlapping motor and nonmotor symptoms of depression, adjusted instrument cutoff scores may be needed for dPD, and scales to assess severity of motor symptoms (e.g., UPDRS) should also be included to help adjust for confounding factors. The HADS and the GDS include limited motor symptom assessment and may, therefore, be most useful in rating depression severity across a range of PD severity; however, these scales appear insensitive in severe depression. The complex and time‐consuming task of developing a new scale to measure depression specifically for patients with PD is currently not warranted. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Anette Schrag MD, PhD</name><affiliations><json:string>University Department of Clinical Neurosciences, Royal Free and University College Medical School, London NW3 2PF, United Kingdom</json:string></affiliations></json:item><json:item><name>Paolo Barone MD</name><affiliations><json:string>Department of Neurological Sciences, University of Napoli Federico II, Naples, Italy</json:string></affiliations></json:item><json:item><name>Richard G. Brown PhD</name><affiliations><json:string>King's College London, MRC Neurodegeneration Research Centre, Institute of Psychiatry, Department of Psychology, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Albert F.G. Leentjens MD, PhD</name><affiliations><json:string>Department of Psychiatry, Maastricht University Hospital, Maastricht, The Netherlands</json:string></affiliations></json:item><json:item><name>William M. McDonald MD</name><affiliations><json:string>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA</json:string></affiliations></json:item><json:item><name>Sergio Starkstein MD</name><affiliations><json:string>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Australia</json:string></affiliations></json:item><json:item><name>Daniel Weintraub MD</name><affiliations><json:string>Department of Psychiatry, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, University Hospital, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD</name><affiliations><json:string>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</json:string></affiliations></json:item><json:item><name>Cristina Sampaio MD</name><affiliations><json:string>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</json:string></affiliations></json:item><json:item><name>Glenn T. Stebbins PhD</name><affiliations><json:string>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Christopher G. Goetz MD</name><affiliations><json:string>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>depression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>psychometrics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>psychiatric status rating scales</value></json:item></subject><articleId><json:string>MDS21333</json:string></articleId><language><json:string>eng</json:string></language><abstract>Depression is a common comorbid condition in Parkinson's disease (PD) and a major contributor to poor quality of life and disability. However, depression can be difficult to assess in patients with PD due to overlapping symptoms and difficulties in the assessment of depression in cognitively impaired patients. As several rating scales have been used to assess depression in PD (dPD), the Movement Disorder Society commissioned a task force to assess their clinimetric properties and make clinical recommendations regarding their use. A systematic literature review was conducted to explore the use of depression scales in PD and determine which scales should be selected for this review. The scales reviewed were the Beck Depression Inventory (BDI), Hamilton Depression Scale (Ham‐D), Hospital Anxiety and Depression Scale (HADS), Zung Self‐Rating Depression Scale (SDS), Geriatric Depression Scale (GDS), Montgomery‐Asberg Depression Rating Scale (MADRS), Unified Parkinson's Disease Rating Scale (UPDRS) Part I, Cornell Scale for the Assessment of Depression in Dementia (CSDD), and the Center for Epidemiologic Studies Depression Scale (CES‐D). Seven clinical researchers with clinical and research experience in the assessment of dPD were assigned to review the scales using a structured format. The most appropriate scale is dependent on the clinical or research goal. However, observer‐rated scales are preferred if the study or clinical situation permits. For screening purposes, the HAM‐D, BDI, HADS, MADRS, and GDS are valid in dPD. The CES‐D and CSDD are alternative instruments that need validation in dPD. For measurement of severity of depressive symptoms, the Ham‐D, MADRS, BDI, and SDS scales are recommended. Further studies are needed to validate the CSDD, which could be particularly useful for the assessment of severity of dPD in patients with comorbid dementia. To account for overlapping motor and nonmotor symptoms of depression, adjusted instrument cutoff scores may be needed for dPD, and scales to assess severity of motor symptoms (e.g., UPDRS) should also be included to help adjust for confounding factors. The HADS and the GDS include limited motor symptom assessment and may, therefore, be most useful in rating depression severity across a range of PD severity; however, these scales appear insensitive in severe depression. The complex and time‐consuming task of developing a new scale to measure depression specifically for patients with PD is currently not warranted. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>2537</abstractCharCount><pdfWordCount>11648</pdfWordCount><pdfCharCount>75528</pdfCharCount><pdfPageCount>16</pdfPageCount><abstractWordCount>379</abstractWordCount></qualityIndicators><title>Depression rating scales in Parkinson's disease: Critique and recommendations</title><genre><json:string>article</json:string></genre><host><volume>22</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>16</total><last>1092</last><first>1077</first></pages><issn><json:string>0885-3185</json:string></issn><issue>8</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21333</json:string></doi><id>E10BA9A996EAA2019D3CAC78E33B7FE57DA9CEA7</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E10BA9A996EAA2019D3CAC78E33B7FE57DA9CEA7/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/E10BA9A996EAA2019D3CAC78E33B7FE57DA9CEA7/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E10BA9A996EAA2019D3CAC78E33B7FE57DA9CEA7/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Depression rating scales in Parkinson's disease: Critique and recommendations</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2007</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Depression rating scales in Parkinson's disease: Critique and recommendations</title><author><persName><forename type="first">Anette</forename><surname>Schrag</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: University Department of Clinical Neurosciences, Royal Free and University College Medical School, London NW3 2PF, UK</p></note><affiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, London NW3 2PF, United Kingdom</affiliation></author><author><persName><forename type="first">Paolo</forename><surname>Barone</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Sciences, University of Napoli Federico II, Naples, Italy</affiliation></author><author><persName><forename type="first">Richard G.</forename><surname>Brown</surname></persName><roleName type="degree">PhD</roleName><affiliation>King's College London, MRC Neurodegeneration Research Centre, Institute of Psychiatry, Department of Psychology, London, United Kingdom</affiliation></author><author><persName><forename type="first">Albert F.G.</forename><surname>Leentjens</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Psychiatry, Maastricht University Hospital, Maastricht, The Netherlands</affiliation></author><author><persName><forename type="first">William M.</forename><surname>McDonald</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA</affiliation></author><author><persName><forename type="first">Sergio</forename><surname>Starkstein</surname></persName><roleName type="degree">MD</roleName><affiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Australia</affiliation></author><author><persName><forename type="first">Daniel</forename><surname>Weintraub</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Psychiatry, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA</affiliation></author><author><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><roleName type="degree">MD</roleName><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</affiliation></author><author><persName><forename type="first">Cristina</forename><surname>Sampaio</surname></persName><roleName type="degree">MD</roleName><affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</affiliation></author><author><persName><forename type="first">Glenn T.</forename><surname>Stebbins</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Christopher G.</forename><surname>Goetz</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-06-15"></date><biblScope unit="volume">22</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1077">1077</biblScope><biblScope unit="page" to="1092">1092</biblScope></imprint></monogr><idno type="istex">E10BA9A996EAA2019D3CAC78E33B7FE57DA9CEA7</idno><idno type="DOI">10.1002/mds.21333</idno><idno type="ArticleID">MDS21333</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Depression is a common comorbid condition in Parkinson's disease (PD) and a major contributor to poor quality of life and disability. However, depression can be difficult to assess in patients with PD due to overlapping symptoms and difficulties in the assessment of depression in cognitively impaired patients. As several rating scales have been used to assess depression in PD (dPD), the Movement Disorder Society commissioned a task force to assess their clinimetric properties and make clinical recommendations regarding their use. A systematic literature review was conducted to explore the use of depression scales in PD and determine which scales should be selected for this review. The scales reviewed were the Beck Depression Inventory (BDI), Hamilton Depression Scale (Ham‐D), Hospital Anxiety and Depression Scale (HADS), Zung Self‐Rating Depression Scale (SDS), Geriatric Depression Scale (GDS), Montgomery‐Asberg Depression Rating Scale (MADRS), Unified Parkinson's Disease Rating Scale (UPDRS) Part I, Cornell Scale for the Assessment of Depression in Dementia (CSDD), and the Center for Epidemiologic Studies Depression Scale (CES‐D). Seven clinical researchers with clinical and research experience in the assessment of dPD were assigned to review the scales using a structured format. The most appropriate scale is dependent on the clinical or research goal. However, observer‐rated scales are preferred if the study or clinical situation permits. For screening purposes, the HAM‐D, BDI, HADS, MADRS, and GDS are valid in dPD. The CES‐D and CSDD are alternative instruments that need validation in dPD. For measurement of severity of depressive symptoms, the Ham‐D, MADRS, BDI, and SDS scales are recommended. Further studies are needed to validate the CSDD, which could be particularly useful for the assessment of severity of dPD in patients with comorbid dementia. To account for overlapping motor and nonmotor symptoms of depression, adjusted instrument cutoff scores may be needed for dPD, and scales to assess severity of motor symptoms (e.g., UPDRS) should also be included to help adjust for confounding factors. The HADS and the GDS include limited motor symptom assessment and may, therefore, be most useful in rating depression severity across a range of PD severity; however, these scales appear insensitive in severe depression. The complex and time‐consuming task of developing a new scale to measure depression specifically for patients with PD is currently not warranted. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>depression</term></item><item><term>Parkinson's disease</term></item><item><term>psychometrics</term></item><item><term>psychiatric status rating scales</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-10-24">Received</change><change when="2006-10-28">Registration</change><change when="2007-06-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/E10BA9A996EAA2019D3CAC78E33B7FE57DA9CEA7/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="80"><doi origin="wiley" registered="yes">10.1002/mds.v22:8</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">8</numbering></numberingGroup><coverDate startDate="2007-06-15">15 June 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="40" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21333</doi><idGroup><id type="unit" value="MDS21333"></id></idGroup><countGroup><count type="pageTotal" number="16"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2006-10-24"></event><event type="manuscriptRevised" date="2006-10-24"></event><event type="manuscriptAccepted" date="2006-10-28"></event><event type="firstOnline" date="2007-03-29"></event><event type="publishedOnlineFinalForm" date="2007-06-19"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2007-03-29"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1077</numbering><numbering type="pageLast">1092</numbering></numberingGroup><correspondenceTo>University Department of Clinical Neurosciences, Royal Free and University College Medical School, London NW3 2PF, UK</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21333.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="183"></count><count type="wordTotal" number="13040"></count></countGroup><titleGroup><title type="main" xml:lang="en">Depression rating scales in Parkinson's disease: Critique and recommendations</title><title type="short" xml:lang="en">Depression Rating Scales in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Anette</givenNames><familyName>Schrag</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>a.schrag@medsch.ucl.ac.uk</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Paolo</givenNames><familyName>Barone</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Richard G.</givenNames><familyName>Brown</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Albert F.G.</givenNames><familyName>Leentjens</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>William M.</givenNames><familyName>McDonald</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Sergio</givenNames><familyName>Starkstein</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Daniel</givenNames><familyName>Weintraub</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af9"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Cristina</givenNames><familyName>Sampaio</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af11"><personName><givenNames>Glenn T.</givenNames><familyName>Stebbins</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af11"><personName><givenNames>Christopher G.</givenNames><familyName>Goetz</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, London NW3 2PF, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="IT" type="organization"><unparsedAffiliation>Department of Neurological Sciences, University of Napoli Federico II, Naples, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="GB" type="organization"><unparsedAffiliation>King's College London, MRC Neurodegeneration Research Centre, Institute of Psychiatry, Department of Psychology, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="NL" type="organization"><unparsedAffiliation>Department of Psychiatry, Maastricht University Hospital, Maastricht, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="AU" type="organization"><unparsedAffiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Australia</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, University Hospital, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="FR" type="organization"><unparsedAffiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="PT" type="organization"><unparsedAffiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</unparsedAffiliation></affiliation><affiliation xml:id="af11" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">depression</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">psychometrics</keyword><keyword xml:id="kwd4">psychiatric status rating scales</keyword></keywordGroup><supportingInformation><p> This article includes supplementary material available online at <url href="http://www.interscience.wiley.com/jpages/0885-3185/suppmat"> http://www.interscience.wiley.com/jpages/0885‐3185/suppmat </url> . </p><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds21333:jws-mds"></mediaResource><caption>Supporting Information file jws‐mds.21333.doc</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Depression is a common comorbid condition in Parkinson's disease (PD) and a major contributor to poor quality of life and disability. However, depression can be difficult to assess in patients with PD due to overlapping symptoms and difficulties in the assessment of depression in cognitively impaired patients. As several rating scales have been used to assess depression in PD (dPD), the Movement Disorder Society commissioned a task force to assess their clinimetric properties and make clinical recommendations regarding their use. A systematic literature review was conducted to explore the use of depression scales in PD and determine which scales should be selected for this review. The scales reviewed were the Beck Depression Inventory (BDI), Hamilton Depression Scale (Ham‐D), Hospital Anxiety and Depression Scale (HADS), Zung Self‐Rating Depression Scale (SDS), Geriatric Depression Scale (GDS), Montgomery‐Asberg Depression Rating Scale (MADRS), Unified Parkinson's Disease Rating Scale (UPDRS) Part I, Cornell Scale for the Assessment of Depression in Dementia (CSDD), and the Center for Epidemiologic Studies Depression Scale (CES‐D). Seven clinical researchers with clinical and research experience in the assessment of dPD were assigned to review the scales using a structured format. The most appropriate scale is dependent on the clinical or research goal. However, observer‐rated scales are preferred if the study or clinical situation permits. For <i>screening</i> purposes, the HAM‐D, BDI, HADS, MADRS, and GDS are valid in dPD. The CES‐D and CSDD are alternative instruments that need validation in dPD. For measurement of <i>severity</i> of depressive symptoms, the Ham‐D, MADRS, BDI, and SDS scales are recommended. Further studies are needed to validate the CSDD, which could be particularly useful for the assessment of severity of dPD in patients with comorbid dementia. To account for overlapping motor and nonmotor symptoms of depression, adjusted instrument cutoff scores may be needed for dPD, and scales to assess severity of motor symptoms (e.g., UPDRS) should also be included to help adjust for confounding factors. The HADS and the GDS include limited motor symptom assessment and may, therefore, be most useful in rating depression severity across a range of PD severity; however, these scales appear insensitive in severe depression. The complex and time‐consuming task of developing a new scale to measure depression specifically for patients with PD is currently not warranted. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Depression rating scales in Parkinson's disease: Critique and recommendations</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Depression Rating Scales in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Depression rating scales in Parkinson's disease: Critique and recommendations</title></titleInfo><name type="personal"><namePart type="given">Anette</namePart><namePart type="family">Schrag</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, London NW3 2PF, United Kingdom</affiliation><description>Correspondence: University Department of Clinical Neurosciences, Royal Free and University College Medical School, London NW3 2PF, UK</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paolo</namePart><namePart type="family">Barone</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences, University of Napoli Federico II, Naples, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard G.</namePart><namePart type="family">Brown</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>King's College London, MRC Neurodegeneration Research Centre, Institute of Psychiatry, Department of Psychology, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Albert F.G.</namePart><namePart type="family">Leentjens</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Psychiatry, Maastricht University Hospital, Maastricht, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">William M.</namePart><namePart type="family">McDonald</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sergio</namePart><namePart type="family">Starkstein</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Daniel</namePart><namePart type="family">Weintraub</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cristina</namePart><namePart type="family">Sampaio</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Glenn T.</namePart><namePart type="family">Stebbins</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christopher G.</namePart><namePart type="family">Goetz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-06-15</dateIssued><dateCaptured encoding="w3cdtf">2006-10-24</dateCaptured><dateValid encoding="w3cdtf">2006-10-28</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">183</extent><extent unit="words">13040</extent></physicalDescription><abstract lang="en">Depression is a common comorbid condition in Parkinson's disease (PD) and a major contributor to poor quality of life and disability. However, depression can be difficult to assess in patients with PD due to overlapping symptoms and difficulties in the assessment of depression in cognitively impaired patients. As several rating scales have been used to assess depression in PD (dPD), the Movement Disorder Society commissioned a task force to assess their clinimetric properties and make clinical recommendations regarding their use. A systematic literature review was conducted to explore the use of depression scales in PD and determine which scales should be selected for this review. The scales reviewed were the Beck Depression Inventory (BDI), Hamilton Depression Scale (Ham‐D), Hospital Anxiety and Depression Scale (HADS), Zung Self‐Rating Depression Scale (SDS), Geriatric Depression Scale (GDS), Montgomery‐Asberg Depression Rating Scale (MADRS), Unified Parkinson's Disease Rating Scale (UPDRS) Part I, Cornell Scale for the Assessment of Depression in Dementia (CSDD), and the Center for Epidemiologic Studies Depression Scale (CES‐D). Seven clinical researchers with clinical and research experience in the assessment of dPD were assigned to review the scales using a structured format. The most appropriate scale is dependent on the clinical or research goal. However, observer‐rated scales are preferred if the study or clinical situation permits. For screening purposes, the HAM‐D, BDI, HADS, MADRS, and GDS are valid in dPD. The CES‐D and CSDD are alternative instruments that need validation in dPD. For measurement of severity of depressive symptoms, the Ham‐D, MADRS, BDI, and SDS scales are recommended. Further studies are needed to validate the CSDD, which could be particularly useful for the assessment of severity of dPD in patients with comorbid dementia. To account for overlapping motor and nonmotor symptoms of depression, adjusted instrument cutoff scores may be needed for dPD, and scales to assess severity of motor symptoms (e.g., UPDRS) should also be included to help adjust for confounding factors. The HADS and the GDS include limited motor symptom assessment and may, therefore, be most useful in rating depression severity across a range of PD severity; however, these scales appear insensitive in severe depression. The complex and time‐consuming task of developing a new scale to measure depression specifically for patients with PD is currently not warranted. © 2007 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>depression</topic><topic>Parkinson's disease</topic><topic>psychometrics</topic><topic>psychiatric status rating scales</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><note type="content"> This article includes supplementary material available online at http://www.interscience.wiley.com/jpages/0885‐3185/suppmat .Supporting Info Item: Supporting Information file jws‐mds.21333.doc - </note><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1077</start><end>1092</end><total>16</total></extent></part></relatedItem><identifier type="istex">E10BA9A996EAA2019D3CAC78E33B7FE57DA9CEA7</identifier><identifier type="DOI">10.1002/mds.21333</identifier><identifier type="ArticleID">MDS21333</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001342 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001342 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:E10BA9A996EAA2019D3CAC78E33B7FE57DA9CEA7
|texte= Depression rating scales in Parkinson's disease: Critique and recommendations
}}
| This area was generated with Dilib version V0.6.23. |  |